PRISMA and EU MDR Literature Review: A Guide to Structured Evidence Methodology

How PRISMA Principles Support Transparent and Defensible Medical Device Literature Reviews

Literature reviews play an increasingly important role in demonstrating the safety and performance of medical devices under EU MDR 2017/745, the EU Medical Device Regulation that applies directly across the European Union without national transposition. Regulatory expectations have evolved significantly beyond the simple identification of published studies. Manufacturers must now demonstrate that literature review activities are performed using structured, transparent, and reproducible methodologies capable of supporting broader clinical evaluation and benefit-risk conclusions.

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) provides a structured framework for improving transparency and consistency within literature review workflows. Although PRISMA was not developed specifically for EU MDR compliance, several of its core principles align closely with broader expectations surrounding traceability, reproducibility, and defensibility within clinical evaluation activities.

This article explores the relevance of PRISMA principles within medical device literature reviews under EU MDR, including their relationship to structured review methodology, regulatory defensibility, and ongoing clinical evidence management.

Why Literature Review Methodology Matters Under EU MDR

Literature reviews are a key component of the clinical evaluation process, helping manufacturers demonstrate how published evidence supports a device’s safety, performance, and benefit-risk conclusions. Article 61 and Annex XIV outline expectations surrounding the clinical evaluation process, including the use of relevant clinical data and systematic approaches to evidence identification and assessment.

Manufacturers are increasingly expected to demonstrate not only which evidence was included within a literature review, but also how that evidence was identified, screened, evaluated, and selected. This has increased the importance of transparent and reproducible literature review methodologies capable of supporting broader clinical evaluation conclusions.

Structured literature review processes support greater consistency in database selection, search strategy development, screening rationale, and evidence traceability throughout the review lifecycle. For manufacturers, this improves the transparency of clinical evidence activities and reduces ambiguity surrounding inclusion and exclusion decisions during regulatory review.

The quality of a literature review depends not only on the evidence ultimately identified, but also on the methodology used to evaluate, document, and justify the selection of that evidence. Weaknesses in review methodology, limited transparency, or inadequate documentation reduce confidence in the overall reliability and defensibility of the clinical evaluation process.

What is PRISMA?

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is a structured reporting framework originally developed to improve the transparency and consistency of systematic reviews and evidence synthesis activities. Although primarily associated with academic and research environments, PRISMA principles have become increasingly relevant within broader literature review workflows used to support clinical evaluation activities under EU MDR.

PRISMA 2020 includes a 27-item checklist and updated flow diagram intended to support more complete and transparent reporting of systematic reviews. The framework supports a more structured approach to documenting how evidence is identified, screened, evaluated, and ultimately included within a review process.

PRISMA-based workflows typically include several core stages: literature identification, screening, eligibility assessment, and final evidence inclusion. These stages help establish a clearer audit trail regarding how evidence was evaluated and why particular studies were included or excluded from the final review.

Importantly, PRISMA does not define the quality of the underlying evidence or replace the need for critical appraisal and clinical interpretation. Rather, it supports more transparent documentation of the review methodology used to manage and evaluate clinical literature.

Relevance of PRISMA to Medical Device Literature Reviews

Several core PRISMA principles align closely with broader expectations for transparent and reproducible literature review methodology under EU MDR. Its structured approach to documenting search strategy, screening, and evidence selection supports greater consistency and traceability throughout clinical evidence evaluation activities.

Clear reporting of databases searched, search terms used, date ranges applied, and screening methodology improves reproducibility and helps demonstrate how relevant evidence was identified and assessed. This aligns directly with the documentation expectations outlined in MEDDEV 2.7/1 Rev 4.

PRISMA principles also support greater transparency surrounding study selection and exclusion decisions. Structured screening workflows and documented inclusion and exclusion rationale establish a clearer audit trail regarding how evidence was evaluated and why specific literature was considered relevant to the clinical evaluation.

From a documentation standpoint, this strengthens traceability across Clinical Evaluation Reports, PMS activities, PMCF findings, and broader clinical evidence strategies. It also reduces ambiguity during regulatory review by making the review process easier to follow, reproduce, and update.

As Notified Bodies continue to place greater emphasis on the defensibility of clinical evidence methodologies under EU MDR, structured review workflows help strengthen confidence in the reliability and transparency of literature review activities.

Common Challenges in MDR Literature Reviews

Despite increasing emphasis on structured literature review methodology, practical challenges in evidence review and documentation remain common. In many cases, limitations arise not from the absence of literature review activities, but from inconsistencies in how review methodology is documented, maintained, and integrated within broader clinical evaluation processes.

Poorly documented search strategies, including incomplete reporting of databases searched, search terms used, date ranges applied, or search update procedures, reduce reproducibility and make it more difficult to demonstrate how evidence was systematically identified and evaluated.

Challenges also arise where inclusion and exclusion criteria are inconsistently applied or inadequately justified. Where screening rationale is unclear, traceability between identified literature and final evidence selection becomes difficult to establish during regulatory review. For a detailed breakdown of the most common literature review challenges affecting clinical evaluation submissions, see our dedicated article on this topic.

Fragmented review workflows, where literature searching, screening, appraisal, and CER integration are managed separately, create gaps in documentation consistency and reduce overall transparency within the clinical evidence strategy.

PRISMA and Regulatory Defensibility

For regulatory purposes, PRISMA is most useful when its principles are applied as part of a defensible literature review methodology. The value lies less in referencing PRISMA itself, and more in demonstrating that evidence identification, screening, selection, and documentation were performed in a structured and reproducible way.

During regulatory assessment, the defensibility of a literature review depends on the clarity and reproducibility of the methodology used to identify, screen, evaluate, and document evidence. Inconsistent screening rationale, limited search documentation, or inadequate traceability weaken confidence in the reliability of the overall review process. This is particularly relevant in the context of Clinical Evaluation Report submissions, where methodology gaps are one of the most common reasons reviews are challenged during Notified Body assessment.

Structured review methodologies influenced by PRISMA principles support clearer documentation of search strategies, evidence selection rationale, and screening workflows throughout the clinical evaluation lifecycle. When review findings are integrated into CERs, PMS activities, and PMCF findings, this improves traceability across broader clinical evidence documentation.

The use of structured review methodology does not replace the need for critical appraisal, clinical interpretation, or scientific judgment. Rather, it supports a more transparent and reproducible framework for managing literature review activities and documenting how evidence-based conclusions were established.

Moving Towards Structured Systematic Literature Review Workflows

A structured literature review process is most useful when embedded into the broader clinical evidence lifecycle rather than treated as a standalone search activity. Search strategies, screening decisions, appraisal outcomes, and included evidence should remain traceable to the conclusions they support within the CER, PMS, and PMCF documentation.

This requires more than a well-documented initial review. As new clinical data, post-market findings, or changes in the state of the art emerge, literature review outputs must be reassessed and updated. Maintaining a clear methodology for updates ensures that evidence selection remains consistent over time and that changes to clinical conclusions can be justified.

For manufacturers, the practical goal is to create a review workflow that is structured enough to be reproducible, but flexible enough to remain current as evidence evolves. In this way, literature review becomes part of an ongoing clinical evidence system rather than a one-time evidence collection exercise. Platforms such as CiteMed’s Evidence Cloud are designed specifically to support this integrated approach, embedding literature review within a connected regulatory evidence lifecycle that supports clinical evaluation, post-market surveillance, and PMCF within a single audit-ready environment.

Conclusion

PRISMA principles support more transparent and reproducible literature review workflows by clarifying how evidence is identified, screened, evaluated, and included. While PRISMA is not an EU MDR requirement, its emphasis on structured reporting aligns with the broader need for traceable and defensible clinical evidence documentation required under MEDDEV 2.7/1 Rev 4 and Annex XIV.

For medical device manufacturers, the value lies not in referencing PRISMA as a checklist, but in applying its principles to strengthen review methodology. A well-documented literature review should make the evidence pathway clear: what was searched, what was excluded, what was included, and how those decisions support the clinical evaluation.

If you are reviewing your literature review methodology or preparing for a Clinical Evaluation Report submission and want support building a structured, audit-ready process, Citemeds can help. Get in touch to discuss your requirements.

Frequently Asked Questions

What is PRISMA and why is it relevant to EU MDR literature reviews?

PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) is a structured reporting framework designed to improve the transparency and consistency of systematic reviews. While it was not developed specifically for EU MDR compliance, its core principles align closely with regulatory expectations for traceable, reproducible, and defensible literature review methodology. Under EU MDR 2017/745, manufacturers must demonstrate not only what evidence was included in a review but how it was identified, screened, and selected. PRISMA principles support this by providing a structured framework for documenting each stage of the review process.

Is PRISMA required under EU MDR?

PRISMA is not explicitly required under EU MDR 2017/745 or MEDDEV 2.7/1 Rev 4. However, Notified Bodies widely expect literature reviews to be conducted using structured, transparent, and reproducible methodologies, and PRISMA-based workflows directly support these expectations. The value of PRISMA in a regulatory context lies not in citing it as a requirement, but in applying its principles to demonstrate that evidence identification, screening, selection, and documentation were performed in a methodologically sound and defensible way.

What is a PRISMA flow diagram and how is it used in medical device literature reviews?

A PRISMA flow diagram is a visual summary of how records progressed through each stage of the literature review, from initial identification through to final inclusion. It captures key metrics including records identified, duplicates removed, records screened, records excluded with reasons, and studies ultimately included. In medical device literature reviews under EU MDR, the PRISMA flow diagram provides a clear and auditable record of how the final body of evidence was established, supporting transparency and reproducibility during Notified Body assessment.

How do PRISMA principles strengthen a Clinical Evaluation Report?

Applying PRISMA principles to the literature review underpinning a Clinical Evaluation Report strengthens its defensibility by ensuring that evidence identification, screening, and selection are clearly documented and traceable. This reduces the risk of challenges during Notified Body review related to methodology transparency and reproducibility, which are among the most common reasons CERs are rejected. A well-documented literature review makes it easier to demonstrate how evidence-based conclusions were reached and how the review can be updated as new data emerges.

What are the most common literature review methodology gaps identified during EU MDR regulatory review?

The most common methodology gaps include poorly documented search strategies, inconsistently applied inclusion and exclusion criteria, inadequate screening rationale, fragmented review workflows where literature search and CER integration are managed separately, and limited traceability between identified evidence and final clinical conclusions. These issues are frequently raised by Notified Bodies during conformity assessment and can result in requests for clarification, additional documentation, or significant rework. For a full breakdown, see our article on common literature review challenges.

How does structured literature review methodology support post-market surveillance under EU MDR?

Under EU MDR, post-market surveillance requires manufacturers to continuously monitor the safety and performance of their devices, including through regular literature reviews. A structured review methodology ensures that these ongoing literature activities are conducted using consistent, reproducible processes that remain aligned with the original search strategy and evidence selection criteria. This supports traceability across CERs, PMS reports, and PMCF documentation throughout the device lifecycle, reducing the risk of inconsistencies that could be identified during Notified Body audits.